Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a checkpoint modulator with synthetic lethality to p53 mutants.

Anti-cancer drugs - 1 Nov 2011

Harada Naoki, Watanabe Yoshinori, Yoshimura Yasushi, Sakumoto Hirofumi, Makishima Fusao, Tsuchiya Masayuki, Nakanishi Keiko, Nakanishi Makoto, Aoki Yuko

Abstract excerpt

The G(2) checkpoint is an indispensable pathway for cancers lacking p53 function, for delaying cell cycle progression, and for completing DNA repair. Therefore, disruption of this pathway is expected to offer selective therapy for these highly prevalent cancers. The aim of this study was to identify an inhibitor of the G(2) checkpoint including the ataxia-telangiectasia-mutated and Rad3-related checkpoint kinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to G2 Phase
Share to HT29 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Camptothecin

Share to CDC2 Protein Kinase

Share to Checkpoint Kinase 1

Share to Cyclin B

Share to G1 Phase

Share to Propanolamines

Source

Identifiers

PMID: 21822123
DOI: 10.1097/CAD.0b013e328349dd43

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a checkpoint modulator with synthetic lethality to p53 mutants.PMID 21822123Read ↗

CBP-93872 inhibits NBS1-mediated ATR activation, abrogating maintenance of the DNA double-strand break-specific G2 checkpoint.Semantic proximity Read ↗

Novel Checkpoint 1 InhibitorsSemantic proximity Read ↗

Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.Semantic proximity Read ↗

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1Semantic proximity Read ↗

Chk1 Inhibitors for Novel Cancer TreatmentSemantic proximity Read ↗

Therapeutic Exploitation of Checkpoint Defects in Cancer Cells Lacking p53 FunctionSemantic proximity Read ↗

Checkpoint kinase inhibitors: a review of the patent literatureSemantic proximity Read ↗

Molecular Basis for G2 Arrest Induced by 2′- C -Cyano-2′-Deoxy-1-β- d - Arabino -Pentofuranosylcytosine and Consequences of Checkpoint AbrogationSemantic proximity Read ↗

Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.Semantic proximity Read ↗

Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosisSemantic proximity Read ↗

Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells.Semantic proximity Read ↗

Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.